Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_assertion type Assertion NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_head.
- NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_assertion description "[Reducing the number of weekly treatments per cycle from four to three and adding prophylactic dexamethasone, which abrogated interleukin-6 release and CRS (P < or = .01), resulted in improved tolerability and treatment delivery.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_provenance.
- NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_assertion evidence source_evidence_literature NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_provenance.
- NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_assertion SIO_000772 19826119 NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_provenance.
- NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_assertion wasDerivedFrom befree-20150227 NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_provenance.
- NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_assertion wasGeneratedBy ECO_0000203 NP496953.RAS2msL6Qzpj7F6bZH-zFT7CLJW7enX8Dfx3i8JB2DASs130_provenance.